Orforglipron at Trimi: Why We Are Preparing for the Oral GLP-1

Orforglipron — Eli Lilly's investigational once-daily oral GLP-1 receptor agonist (development code LY3502970) — is the most important pill-based GLP-1 in late-stage development. With Phase 3 ACHIEVE-1 results landing in April 2026 (NCT05869903) and the obesity-specific ATTAIN-1 trial expected to read out late 2026, orforglipron represents a fundamental change in how GLP-1 therapy is delivered. Trimi is preparing to make compounded orforglipron available when legitimate access channels develop.

Why Oral GLP-1 Matters

All currently FDA-approved GLP-1 medications for weight loss are peptides — chains of amino acids that don't survive stomach acid intact. That's why semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) require subcutaneous injection. Even oral semaglutide (Rybelsus) needs special enteric coating plus an absorption enhancer to survive digestion, which is why it requires fasting administration and has lower bioavailability than the injection.

Orforglipron is fundamentally different. It's a small-molecule non-peptide (molecular weight ~750 Da). It binds the GLP-1 receptor with high affinity but isn't built from amino acids, so digestive enzymes can't degrade it. The result: once-daily oral administration without enteric coating, without fasting requirements, with normal absorption characteristics. For patients with needle aversion, the convenience could be transformative.

The Phase 3 Pipeline

ACHIEVE-1 (NCT05869903) — Phase 3 trial in adults with type-2 diabetes. Results read out April 2026. This is the regulatory anchor for FDA approval in diabetes; obesity-specific trials follow.

ATTAIN-1 — Phase 3 trial in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. Results expected late 2026. This trial supports the obesity indication FDA submission.

FDA submission — Eli Lilly is expected to submit New Drug Applications for both indications in 2026-2027.

Commercial launch — expected late 2027 to 2028.

How Orforglipron Compares

Phase 2 data published in the New England Journal of Medicine (Wharton et al., 2023) showed orforglipron at 45 mg daily produced 14.7% mean body-weight reduction at 36 weeks. Comparison context:

• Semaglutide (STEP 1, NEJM 2021): 14.9% mean reduction at 68 weeks — essentially equivalent
• Tirzepatide (SURMOUNT-1, NEJM 2022): 20.9% at 15 mg — more weight loss but injection required
• Retatrutide (Phase 2, NEJM 2023): 24.2% at 12 mg — the highest published GLP-1-class outcome, but earliest launch 2028

Orforglipron's clinical value isn't extra weight loss — it's the oral delivery. Patients who can't or won't inject can now access GLP-1 therapy with outcomes comparable to injectable semaglutide.

The Trimi Approach

Medical-First Philosophy

Every Trimi patient receives a comprehensive medical evaluation before starting any GLP-1 medication. Our board-certified providers review medical history, current medications, contraindications, and individual goals. The oral administration of orforglipron will require careful evaluation of drug-drug interactions (oral medications interact differently than once-weekly injections) and adherence patterns (daily dosing requires different commitment than weekly).

Affordable Access

Trimi's affordability mission anchors orforglipron pricing strategy. Current Trimi pricing:

• Compounded semaglutide: $99/month annual plan
• Compounded tirzepatide: $125/month annual plan
• Compounded orforglipron: pricing to be announced when accessible, consistent with affordability mission

Eli Lilly's brand-name retail pricing for orforglipron is expected to follow their GLP-1 pattern (~$1,000-$1,500/month based on Mounjaro and Zepbound). Trimi will price compounded orforglipron substantially below brand retail when access becomes available through 503A pharmacy partners.

Ongoing Medical Support

GLP-1 treatment is not just a prescription. Trimi provides dose titration guidance, side effect management, medication interaction review (especially important for daily oral dosing), nutritional and lifestyle guidance, and regular check-ins with lab monitoring as appropriate.

Compounded Orforglipron — Regulatory Considerations

Compounded versions of semaglutide and tirzepatide have legal frameworks established under Section 503A of the FFDCA. Orforglipron's compounded availability will depend on:

• FDA classification of orforglipron on the Section 503A bulks list
• Eli Lilly's patent and exclusivity strategy
• FDA enforcement decisions regarding compounding of non-peptide small-molecule GLP-1s (a regulatory category that differs from peptide GLP-1s like semaglutide and tirzepatide)
• Bulk API supply chain availability

The peptide-vs-small-molecule distinction may produce different compounding regulatory dynamics than what we've seen with semaglutide and tirzepatide. Trimi is monitoring FDA classification closely.

Current Treatment Options at Trimi

While orforglipron availability develops, Trimi offers two proven GLP-1 medications today:

Compounded Semaglutide ($99/month annual)

Same active ingredient as FDA-approved Wegovy and Ozempic. Produces 14.9% mean body-weight reduction at 2.4 mg over 68 weeks (STEP 1, NEJM 2021). Most extensive safety data of any GLP-1 class.

Compounded Tirzepatide ($125/month annual)

Same active ingredient as FDA-approved Mounjaro and Zepbound. Produces 20.9% mean body-weight reduction at 15 mg over 72 weeks (SURMOUNT-1, NEJM 2022). Most effective FDA-pathway-cleared weight-loss molecule.

Get Started Today — Reserve Your Orforglipron Waitlist Spot

Do not wait for orforglipron to begin your weight loss journey. Explore Trimi's current treatment options and start with compounded semaglutide ($99/month) or compounded tirzepatide ($125/month). Active Trimi patients automatically receive priority notification when orforglipron becomes accessible. Learn how Trimi works.